1. Introduction {#sec1}
===============

Galectin-1, which is part of a larger family of carbohydrate-binding proteins with an affinity for beta-galactosides, is known to have anti-inflammatory and proangiogenic effects \[[@bib1]\]. Recent studies have shown that galectin expression is upregulated in adipose tissue of mice with high-fat-diet-induced obesity \[[@bib2]\] and that serum galectin-1 levels is positively correlated with body fat in children with obesity \[[@bib3]\]. Moreover, we have showed that galectin-1 gene expression in adipose tissue decreased during weight loss in obese patients and increased after overfeeding in healthy subjects \[[@bib4]\]. In line, a study in overweight and obese participants showed that galectin-1 expression in abdominal adipose tissue is regulated by dietary interventions \[[@bib5]\].

Our laboratory recently proposed a functional role of galectin-1 in subcutaneous adipose tissue in individuals with type 2 diabetes (T2D) \[[@bib4]\]. However, it is unclear whether circulating galectin-1 associates with T2D independently of adipose tissue mass. Indeed, little is known about the association between circulating galectin-1 and T2D including correlations with components of the metabolic syndrome. Here, we investigated associations between serum galectin-1, clinical characteristics and inflammatory markers in a large population-based cohort of middle-aged subjects from the Swedish CArdioPulmonary bioImage Study (SCAPIS) pilot.

2. Methods {#sec2}
==========

2.1. Participants {#sec2.1}
-----------------

This study was conducted in participants of the SCAPIS pilot \[[@bib6]\]. It was approved by the Ethical Committee of Gothenburg University and written informed consent was obtained from all participants. In brief, 1111 individuals residing in Gothenburg, Sweden, and aged 50--64 years at the time of invitation participated in the SCAPIS pilot. Serum galectin-1 was not measured in 24 individuals from whom we did not get consent for biomarker analysis or from whom we could not obtain venous blood. Because galectin-1 is associated with cancer, only participants without a medical history of cancer were enrolled. Thus, we excluded those with a medical history of cancer (n = 81) or when a medical history of cancer was not known (n = 12). Individuals with latent autoimmune diabetes of the adult or type 1 diabetes were also excluded (n = 5). In total, 989 individuals were enrolled in the study ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Flowchart of participant selection for the study.Fig. 1

2.2. Blood analysis {#sec2.2}
-------------------

Galectin-1 was measured using the Human Galectin-1 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturers\' instructions. Intra-assay and inter-assay coefficient of variation were 7.1% and 9.5%, respectively. Cytokines were measured in serum using the ultrasensitive multiplex electrochemiluminescence immunoassay (ELISA) (Meso Scale Diagnostics (MSD), Rockville, MD, USA). The human V-PLEX Pro-Inflammatory Panel 1 Human Kit (\#K15049) was used to quantify interferon gamma (IFN-γ), interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and tumor necrosis factor-alpha (TNF-α) according to the manufacturer\'s instructions.

Routine analyses of glucose, insulin, and cholesterol were performed at the Department of Clinical Chemistry, Sahlgrenska University Hospital, on a Cobas instrument (Roche Molecular Diagnostics). The homeostasis model assessment for insulin resistance (HOMA-IR) was calculated using the formula \[glucose\]\*\[insulin\]/22.5 \[[@bib7]\].

2.3. Statistics {#sec2.3}
---------------

Multiple comparisons between groups were tested with Kruskal-Wallis test and Dunn\'s multiple comparisons test post hoc. Single comparisons between groups on continuous variables were calculated using Mann-Whitney *U* test using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA). Chi^2^ -test and Fisher\'s exact test were used for comparing categorical data. Spearman correlations were performed between galectin-1 levels and clinical characteristics of the subjects. To segregate the impact of covariates, two linear models were calculated using SPSS Statistics 25 (IBM, New York, USA). Non-Gaussian distributed variables according to Kolmogorov--Smirnov were log-transformed for near normal distribution in the linear model. *P* values below 0.05 were considered statistically significant for all statistical tests.

3. Results {#sec3}
==========

3.1. Demographics {#sec3.1}
-----------------

Clinical characteristics of the population are presented in [Table 1](#tbl1){ref-type="table"}. The average participant was overweight and men (n = 473) had a higher BMI than women (n = 516). Measures of glucose homeostasis including glucose and insulin, but not HbA1c, were higher in men than women. Total cholesterol and high-density lipoprotein (HDL) cholesterol were higher in women whereas triglyceride levels were higher in men. Low-density lipoprotein (LDL) cholesterol levels were similar in men and women.Table 1Clinical characteristics of the study population.Table 1WomenMen*p value*n (%)473 (48)516 (52)Age, years57 \[54; 61\]57 \[54; 62\]ns.BMI, kg/m^2^26.0 \[23.5; 29,2\]27.2 \[25.1; 29.5\]**\<0.01**Waist, cm89 \[81; 98\]99 \[94; 105\]**\<0.01**Systolic blood pressure, mmHg120 \[111; 130\]125 \[116; 136\]**\<0.01**Diastolic blood pressure, mmHg72 \[66; 78\]77 \[72; 83\]**\<0.01**Current smoker, n (%)93 (20)93 (18)ns.Current employment, n (%)355 (75)391 (76)ns.Galectin-1, ng/mL22.7 \[19.8; 26.1\]21.5 \[18.9; 24.8\]**\<0.05**Glucose, mmol/L5.5 \[5.1; 5.8\]5.8 \[5.5; 6.3\]**\<0.01**Insulin, mU/L6.4 \[4.3; 9.1\]7.7 \[5.2; 11.0\]**\<0.01**HbA1c, mmol/mol35 \[33; 37\]35 \[33; 38\]ns.Total Cholesterol, mmol/L5.9 \[5.3; 6,6\]5.6 \[4.8; 6.3\]**\<0.01**LDL-C, mmol/L3.8 \[3.1; 4.5\]3.8 \[3.1; 4.4\]ns.HDL-C, mmol/L1.8 \[1.5; 2.3\]1.4 \[1.2; 1.7\]**\<0.01**Triglycerides, mmol/L1.0 \[0.74; 1.4\]1.2 \[0.91; 1.8\]**\<0.01**Creatinine, μmol/L70 \[63; 77\]86 \[79; 94\]**\<0.02**ALT, μkat/L0.39 \[0.31; 0.50\]0.48 \[0.38; 0.63\]**\<0.01**Hypertension, n (%)135 (29)172 (33)ns.T2D, n (%)19 (4)49 (9)**\<0.01**Prevalent cardiovascular disease^a^, n (%)9 (2)21 (4)**\<0.05**Rheumatic disease, n (%)40 (8)23 (4)**\<0.05**Any prescribed drug, n (%)217 (46)209 (41)ns.Pharmacological diabetes treatment, n (%)9 (2)31 (6)**\<0.01**Statins, n (%)34 (7)49 (9)ns.Betablockers, n (%)32 (7)35 (7)ns.ACE inhibitors or ARB, n (%)54 (11)59 (11)ns.[^1]

3.2. Correlations between galectin-1, clinical, metabolic and inflammatory variables {#sec3.2}
------------------------------------------------------------------------------------

We observed significantly higher levels of galectin-1 in women than in men ([Table 1](#tbl1){ref-type="table"}). Galectin-1 displayed a weak correlation with age and systolic blood pressure ([Fig. 2](#fig2){ref-type="fig"} A and B) but a stronger correlation with waist and BMI circumference ([Fig. 2](#fig2){ref-type="fig"}C and D) and increased step-wise with BMI in both sexes ([Fig. 2](#fig2){ref-type="fig"} E). There was no difference in galectin-1 between participants with (n = 68) or without (n = 921) T2D (Appendix [Table A](#appsec1){ref-type="sec"}). Markers associated with the metabolic syndrome were consistently higher in participants with T2D than in participants without T2D (Appendix [Table A](#appsec1){ref-type="sec"}). Galectin-1 showed positive correlations with glucose, insulin, HOMA, HbA1c, and triglycerides but an inverse relation with HDL ([Fig. 3](#fig3){ref-type="fig"}A--F). Galectin-1 levels also correlated positively with C-reactive protein (CRP), IL-6, TNF-α, and IFN-γ ([Table 2](#tbl2){ref-type="table"}).Fig. 2Spearman correlations between galectin-1 and clinical characteristics. (A) Age, n = 989; (B) systolic blood pressure, n = 979; (C) waist, n = 988 and (D) BMI, n = 989. (E) Galectin-1 in women and men divided according to BMI presented as mean ± standard error of the mean (SEM). \*\*\*p \< 0.001.Fig. 2Fig. 3Spearman correlations between galectin-1 and variables indicating insulin resistance. (A) glucose, n = 982; (B) insulin, n = 989; (C) HOMA, n = 982; (D) HbA1c, n = 987; (E) triglycerides, n = 988 and (F) HDL, n = 989.Fig. 3Table 2Spearman correlations between galectin-1 and inflammatory markers.Table 2r*p value*nCRP0.27**\<0.001**989TNF-α0.24**\<0.001**989IFN-γ0.08**\<0.05**989IL-1β−0.00ns.989IL-20.05ns.989IL-4−0.01ns.989IL-60.20**\<0.001**989IL-80.02ns.989IL-100.03ns.989IL-12 p700.04ns.989IL-13−0.01ns.989[^2]

3.3. Independent predictors of galectin-1 {#sec3.3}
-----------------------------------------

To adjust for covariates associated with galectin-1, a linear model was used. We first tested the impact of age, sex, BMI and T2D and showed that they were all significant independent predictors of galectin-1 ([Table 3](#tbl3){ref-type="table"}). Interestingly, participants with T2D were predicted to have lower galectin-1 levels than non-diabetic participants and women were predicted to have higher galectin-1 levels than men, when confounding variables were accounted for. Furthermore, galectin-1 was predicted to increase with age and for every unit increase in BMI.Table 3Linear model predicting Ln Galectin-1 based on T2D, sex, age and BMI (Model 1), and a second model predicting Ln Galectin-1 based on sex, age, BMI, and markers of insulin resistance and subclinical inflammation (Model 2).Table 3ParameterβSE95% CISig.LowerUpperModel 1Female sex0.060.010.040.09**\<0.01**Ln Age (years)0.500.090.330.67**\<0.01**Ln BMI0.610.040.530.70**\<0.01**T2D−0.050.03−0.110.00**\<0.05**Model 2Female sex0.060.010.030.08**\<0.01**Ln Age (years)0.500.090.330.67**\<0.01**Ln BMI0.480.060.370.59**\<0.01**Ln Glucose−0.130.05−0.22−0.04**\<0.01**Ln S-Insulin0.040.010.010.07**\<0.01**Ln CRP0.020.010.010.04**\<0.01**[^3]

As type 2 diabetes is a multifactorial disease characterized by both low-grade inflammation and metabolic aberrations, a second linear model was used to determine which characteristic features of T2D could interact with galectin-1. Glucose, insulin and CRP were all independently associated with galectin-1. Of note, glucose was the only parameter in addition to T2D that demonstrated an inverse relationship with galectin-1 ([Table 3](#tbl3){ref-type="table"}).

4. Discussion {#sec4}
=============

This study investigated the association between galectin-1 and variables of the metabolic syndrome in a large cohort of middle-aged Swedish subjects. We show that galectin-1 is inversely associated with type T2D independent of obesity and that age, sex, BMI, insulin, CRP and glucose were all independent predictors of galectin-1.

The correlations observed for galectin-1 and clinical parameters in this cohort are in agreement with previously observed associations between galectin-1 and variables of the metabolic syndrome \[[@bib3],[@bib4]\]. Variables showing the strongest correlations with galectin-1 in this study were markers of obesity and insulin resistance. BMI, waist, insulin and triglycerides had a stronger correlation with galectin-1 than markers of glycemia such as glucose and HbA1c. In line with the observed associations, recent animal studies have indicated a role for galectin-1 in obesity \[[@bib2],[@bib8], [@bib9], [@bib10]\]. In rats, treatment with the galectin-1 inhibitor thiodigalactoside induced weight loss and suppressed triglyceride synthesis and lipid storage, suggesting that the inhibitor interferes with lipid droplet formation \[[@bib8]\]. Additional animal studies on galectin-1 and adiposity also support the relevance of galectin-1 in adipose tissue physiology \[[@bib2]\]. However, further studies are required to determine the functional role of galectin-1 in lipid metabolism.

Surprisingly, galectin-1 was predicted to be lower in participants with T2D compared with non-diabetic participants after adjusting for age, sex and BMI. The paradoxical finding of an inverse association between galectin-1 and T2D could indicate a downregulation of galectin-1 by genetic factors or glucose per se \[[@bib3],[@bib11]\] that may happen in predisposed individuals. The inverse association between glucose and galectin-1 in the linear model further strengthens such a concept. In line with this hypothesis, it has been reported that women with a genetic predisposition in chromosome 22 who develop gestational diabetes present an inability to increase galectin-1 in the later parts of pregnancy, in contrast to healthy pregnant women \[[@bib11]\]. Of note, in this study women displayed higher serum galectin-1 compared with men, and sex predicted galectin-1 in the linear models. Similar observations were made in a small sample of 38 healthy controls in a recent study in cancer patients \[[@bib12]\]. Longitudinal studies of large cohorts are required to address whether the association between galectin-1 and T2D differs between women and men.

Despite the inverse association between T2D and galectin-1 it is possible that associations between galectin-1 and facets of the metabolic syndrome shown in this study indicate increased diabetes risk. It is well known that subclinical inflammation measured as IL-6 and TNF-α in the adipose tissue links obesity to insulin resistance \[[@bib13],[@bib14]\]. Therefore, it was interesting that serum levels of these cytokines also presented the closest correlation with galectin-1 in this study. Results from the linear model that included CRP (chosen because it was the inflammatory marker with the strongest correlation to galectin-1) showed that CRP associated with galectin-1 independent of glucose and insulin levels. This is important as galectin-1 has been widely investigated in inflammatory conditions including different cancers \[[@bib15]\], and inhibitors of galectin-1 are undergoing clinical trials within this field \[[@bib16]\].

In conclusion, galectin-1 was associated with T2D independent of obesity in a cross-sectional study of middle-aged subjects. Furthermore, galectin-1 was associated with several different markers of metabolic disease. These results warrant prospective and functional studies on the role of galectin-1 in T2D.
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[^1]: BMI: body mass index; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; ALT: alanine aminotransferase; ACE inhibitor: angiotensin II converting enzyme inhibitor; ARB: angiotensin II receptor blocker. HbA1c, ref value: 31--46 mmol/mol. Data are presented as n (%) or median \[1st; 3rd quartile\] for categorical data and continuous data respectively. ^a^ Medical history of acute myocardial infarction, stroke, percutaneous coronary intervention, or radiological examinations demonstrating coronary artery stent or graft.

[^2]: IFN- γ: interferon gamma; IL: interleukin; TNF-α: tumor necrosis factor alpha.

[^3]: BMI: body mass index; CRP: C-reactive protein. Galectin-1, age, BMI, glucose, insulin and CRP were log transformed with the natural logarithm (ln).
